- Home
- Automated
- List of product information
- VOREN SUPPOSITORY 12.5 MG [SIN06614P]
VOREN SUPPOSITORY 12.5 MG [SIN06614P]
Active ingredients: VOREN SUPPOSITORY 12.5 MG
Last updated 26 October 2025
On this page
Product Info
VOREN SUPPOSITORY 12.5 MG
[SIN06614P]
Product information
Active Ingredient and Strength | DICLOFENAC SODIUM - 12.5 MG |
Dosage Form | SUPPOSITORY |
Manufacturer and Country | Y S P INDUSTRIES (M) SDN BHD - MALAYSIA |
Registration Number | SIN06614P |
Licence Holder | YUNG SHIN PHARMACEUTICAL (SINGAPORE) PTE LTD |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | M01AB05 |
Indication(s):
Chronic rheumatic arthritis, degenerative osteoarthritis and painful post-operative inflammation.
Dosage and Administration:
Adult: 100mg, usually to be used at night. Maximum total daily dose is 150mg.
Children: 0.5 – 2mg/kg body weight daily, in 2 – 3 divided doses.
Special populations:
Established cardiovascular disease or significant cardiovascular risk factors
The use of high dose diclofenac (150mg/day) for more than 4 weeks is contraindicated in patients with established cardiovascular disease (congestive heart failure, established ischemic heart disease, peripheral arterial disease) or uncontrolled hypertension. If diclofenac treatment is needed, patients with established cardiovascular disease, uncontrolled hypertension or significant cardiovascular risk factors (e.g. hypertension, hyperlipidaemia, diabetes mellitus and smoking) should be treated only after careful consideration and at doses ≤100mg daily if the treatment is for more than 4 weeks. As the cardiovascular risks of diclofenac may increase with dose and duration of exposure, diclofenac should always be prescribed at the lowest effective daily dose and for the shortest duration possible.
To be inserted deep into the rectum.
To be dispensed by the physician's prescription.
Contraindication(s):
Voren suppository should not be used in patients who have shown hypersensitivity to Diclofenac Sodium.
It is contraindicated in patients with any inflammatory lesions of the rectum or anus, and in patients with recent history of rectal and anal bleeding.
It should not be given to children under 12 months of age.
It is contraindicated in patients with active or suspected peptic ulcer or gastric-intestinal bleeding.
It is contraindicated in patients in whom attack of asthma, urticaria or acute rhinitis are precipitated by aspirin or other NSAIDs.
The use of high dose diclofenac (150mg/day) for more than 4 weeks is contraindicated in patients with established cardiovascular disease (congestive heart failure, established ischemic heart disease, peripheral arterial disease) or uncontrolled hypertension.